Background: Indinavir, one component in the HAART regimen, plays an important role in the current treatment of HIV-infection and AIDS. Availability and accessibility of qualified generic indinavir to patients may be the keys for the success of treatment. Objective: Compare the rate and extent of absorption of a generic indinavir formulation with those of an original formulation in healthy Thai volunteers. Method: A randomized, two-period, two-treatment, two-sequence, crossover study with a two-week washout period was performed. A single dose of 2×400 mg indinavir capsules of each formulation was administered to 24 volunteers after an overnight fast. Indinavir plasma concentrations up to 10 hours postdose were determined using high-performance liquid chromatography. Relevant pharmacokinetic parameters were derived and tested for statistically significant differences using ANOVA and criteria of bioequivalence determination were applied. Results: No statistically significant differences were demonstrated for pharmacokinetic parameters including Cmax, Tmax, AUC0-t, and AUC0-∞ derived from the two formulations (n=23, p>0.05). The criteria of bioequivalence determination i.e., the 90% confidence intervals on the mean ratio (generic/original formulation) of natural logarithmtransformed values of Cmax, AUC0-t and AUC0-∞ were 86.3-106.5%, 94.0-108.5%, and 93.9-108.5%, respectively. Conclusion: As the mean ratios of Cmax, AUC0-t and AUC0-∞ of the generic and original formulations were entirely within the guideline range of bioequivalence (80.0-125.0%), the two formulations were considered bioequivalent in terms of rate and extent of absorption.
1. Wainberg MA. Generic HIV drugs-enlightened policy for global health. N Engl J Med. 2005; 352:747-50.
2. Bartlett JA, Muro EP. Generic and branded drugs for the treatment of people living with HIV/AIDS. J Int Assoc Physicians AIDS Care. 2007; 6:15-23.
3. Hugen PWH, Burger DM, ter Hofstede HJM, Koopmans PP, Hekster YA. Development of an indinavir oral liquid for children. Am J Health Syst Pharm. 2000; 57:1332-9.
4. Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother. 1998; 42:332-8.
5. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998; 42:2784-91.
6. The United States Pharmacopoeial Convention, Inc. The United States Pharmacopeia 26 / National Formulary 21. Rockville, USA; 2003.
7. Drug Control Division. Thailand Guidelines for the Conduct of Bioavailability and Bioequivalence Studies. Bangkok, Thailand: Food and Drug Administration, Ministry of Public Health; 2000.
8. Poirier JM, Robidou P, Jaillon P. Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography. Ther Drug Monit. 1999; 21:404-10.
9. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry, Bioanalytical Method Validation. Available from: http://www.fda.gov/cder/guidance/index.htm, 2001/[2 June 2005].
10. Wonnacott RJ, Wonnacott TH, editors. Econometrics. New York:John Wiley & Sons, 1970; p. 132.
11. Association of Southeast Asian Nations (ASEAN), Consultative Committee for Standards and Quality- Pharmaceutical Product Working Group. Guidelines for the Conduct of Bioavailability and Bioequivalence Studies. 2004.
12. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Statistical Approaches to Establishing Bioequivalence. January 2001.
13. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, et al. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol. 2004; 44:305-13.
14. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother. 2003; 51:1231-8.
15. Schiffman SS, Zervakis J, Heffron S, Heald AE. Effect of protease inhibitors on the sense of taste. Nutrition. 1999; 15:767-72.